United Therapeutics Corp (UTHR) Stock
Key stats
- Market cap
- $25.37B
- Price / Earnings ratio
- 20.4x
- EPS (TTM)
- $28.57
- Volume
- Loading
- 52-week high
- $614.23
- 52-week low
- $449.58
Source: third-party data provider, as of November 13, 2026
Compare with UTHR
Recent news
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
UTHR
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
UTHR
United Therapeutics Rising Ahead of Next Earnings Report
United Therapeutics Rising Ahead of Next Earnings Report
UTHR
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
UTHRNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 60.11
- MACD 12/26/9
- 13.48
- EMA 9 of MACD
- 15.65
- MACD histogram
- -2.17
- SMA 50
- $538.56
- Price above SMA 50
- EMA 50
- $554.26
- Price above EMA 50
- SMA 200
- $536.21
- Price above SMA 200
- EMA 200
- $531.04
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $7.39 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
UTHRAnalysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
UTHRUnited Therapeutics Rising Ahead of Next Earnings Report
United Therapeutics Rising Ahead of Next Earnings Report
UTHRUnited Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
UTHR
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
UTHR
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
UTHR
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
UTHR
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
UTHR
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
UTHR
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
UTHRNews tone: automated (AI) classification of the article's content, not a price prediction.
About United Therapeutics Corp
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO | 1955 |
| Mr. Michael I. Benkowitz | President & COO | 1972 |
| Mr. James C. Edgemond | CFO & Treasurer | 1968 |
| Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary | 1964 |
| Harrison Silvers | Manager of Investor Relations | — |
| Ms. Holly Hobson | Associate Vice President of Human Resources | — |
| Mr. Patrick Poisson | Executive Vice President of Strategic Development | 1968 |
| Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation | — |
| Mr. Gil Golden | Senior VP & Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 60.11
- MACD 12/26/9
- 13.48
- EMA 9 of MACD
- 15.65
- MACD histogram
- -2.17
- SMA 50
- $538.56
- Price above SMA 50
- EMA 50
- $554.26
- Price above EMA 50
- SMA 200
- $536.21
- Price above SMA 200
- EMA 200
- $531.04
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $321.00
- Average
- $651.44
- High
- $768.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.6 | +14.2 | ||||||||||
| 2022 | -4.2 | -18.1 | +8.0 | -3.8 | +28.1 | +1.9 | -2.9 | +0.6 | -7.4 | +7.8 | +22.5 | +0.9 |
| 2023 | -3.7 | -5.4 | -8.5 | +2.1 | -9.6 | +3.4 | +8.5 | -6.6 | -1.0 | +0.3 | +7.1 | -8.7 |
| 2024 | -5.5 | +4.5 | -0.9 | +2.7 | +7.8 | +15.3 | -1.8 | +10.9 | +1.7 | +4.5 | -0.9 | -4.7 |
| 2025 | -2.5 | -9.7 | -0.6 | -1.2 | +8.5 | -11.7 | -5.6 | +3.6 | +3.6 | +1.7 | +10.8 | +1.5 |
| 2026 | -5.5 | +6.1 | +15.4 | +0.2 | -2.4 | -0.5 | -5.4 | -1.1 | +5.7 | +4.8 | -0.1 |
